0001209191-24-000319.txt : 20240103 0001209191-24-000319.hdr.sgml : 20240103 20240103160221 ACCESSION NUMBER: 0001209191-24-000319 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240101 FILED AS OF DATE: 20240103 DATE AS OF CHANGE: 20240103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Riley Antony A CENTRAL INDEX KEY: 0001339375 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38052 FILM NUMBER: 24506203 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 94538 FORMER NAME: FORMER CONFORMED NAME: Riley Anthony A DATE OF NAME CHANGE: 20050921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Forte Biosciences, Inc. CENTRAL INDEX KEY: 0001419041 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 261243872 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (310) 618-6994 MAIL ADDRESS: STREET 1: 3060 PEGASUS PARK DRIVE STREET 2: BUILDING 6 CITY: DALLAS STATE: TX ZIP: 75247 FORMER COMPANY: FORMER CONFORMED NAME: Tocagen Inc DATE OF NAME CHANGE: 20071120 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-01-01 0 0001419041 Forte Biosciences, Inc. FBRX 0001339375 Riley Antony A C/O FORTE BIOSCIENCES, INC. 3060 PEGASUS PARK DR., BLDG 6 DALLAS TX 75247 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-01-01 4 M 0 9375 0.00 A 192285 D Common Stock 2024-01-01 4 F 0 3841 0.8217 D 188444 D Restricted Stock Units 2024-01-01 4 M 0 9375 0.00 D Common Stock 9375 112500 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock. On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld. Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1. /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact 2024-01-03